cisplatin,atezolizumab,carboplatin
roche
['muc ,(-much)', 'atezo', 'cisplatin', ' cis ', 'imvigor130', 'lba440', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'nct02807636', 'carboplatin', 'imvigor,11', 'bladder']
the final analysis of imvigor130 showed a trend toward improved os with atezolizumab + plt/gem vs placebo + pl/gem but did not cross the pre-specified boundary for efficacy in itt patients with muc
(hr, 0.85 [95% ci: 0.73, 1.00]; 1-sided p=0.023). #gu23 #bladdercancer 
Jefe de Servicio de Oncología Médica. Hospital Universitario Lucus Augusti, HULA. Grupo de Investigación Oncológica Traslacional, GIOT HULA. Cuenta personal